Security Analysis
The Classic 1940 Edition
(Author) Benjamin Graham"Graham's ideas inspired the investment community for nearly a century."--Smart Money "Graham's method of investing is as relevant today as it was when he first espoused it during the Roaring Twenties."--Investor's Business Daily Benjamin Graham's revolutionary theories have influenced and inspired investors for nearly 70 years. First published in 1934, his Security Analysis is still considered to be the value investing bible for investors of every ilk. Yet, it is the second edition of that book, published in 1940 and long since out of print, that many experts--including Graham protégé Warren Buffet--consider to be the definitive edition. This facsimile reproduction of that seminal work makes available to investors, once again, the original thinking of "this century's (and perhaps history's) most important thinker on applied portfolio investment."
Benjamin Graham
Benjamin Graham (1894-1976) was an influential economist and investor known as the "father of value investing." His most notable work, "The Intelligent Investor," is considered a classic in the field of finance and has had a lasting impact on the investment community. Graham's approach to investing focused on thorough analysis, discipline, and a long-term perspective, which has influenced generations of investors. His emphasis on intrinsic value and margin of safety continues to be a cornerstone of value investing. Graham's writing style is clear, logical, and practical, making his ideas accessible to both professionals and laypeople. Overall, Benjamin Graham's contributions to literature and finance have had a profound impact on the field of investing and continue to be studied and applied today.
Other related
The Intelligent Investor Third Edition
The Definitive Book on Value Investing
The Intelligent Investor, 3rd Ed.
The Definitive Book on Value Investing
Security Analysis, Seventh Edition
Principles and Techniques
Seven Myths About Money
And the Truth About Finding Financial Freedom
Off the Scales
The Inside Story of Ozempic and the Race to Cure Obesity
